## Diagnosis: Atypical Pneumonia due to *Chlamydia pneumoniae* **Key Point:** The clinical triad of persistent cough, low-grade fever, and bilateral interstitial infiltrates on CXR, combined with **negative sputum culture on standard media** and **serological evidence of *C. pneumoniae* infection** (fourfold rise in antibody titre), confirms atypical (walking) pneumonia caused by *Chlamydia pneumoniae*. ## Why *Chlamydia pneumoniae* is an Atypical Pathogen | Feature | *C. pneumoniae* | Typical Bacteria (e.g., *S. pneumoniae*) | |---------|-----------------|------------------------------------------| | **Culture** | Does NOT grow on standard media (blood agar, MacConkey) | Grows readily on standard media | | **Gram stain** | Gram-negative; elementary bodies visible only with special stains | Gram-positive cocci in pairs | | **Presentation** | Insidious onset; interstitial infiltrates; minimal consolidation | Acute onset; lobar consolidation | | **Sputum** | Scant, mucoid; culture negative | Purulent; culture positive | | **Serology** | Diagnostic (fourfold rise in IgG/IgM) | Not diagnostic | **High-Yield:** *C. pneumoniae* causes **atypical (walking) pneumonia** — the patient is ambulatory despite pneumonia, with minimal systemic toxicity. The organism requires special culture media (McCoy cells, HeLa cells) and is best diagnosed by serology or NAAT, NOT routine sputum culture. ## First-Line Treatment **Mnemonic: DAMP** — Doxycycline, Azithromycin (macrolides), Moxifloxacin (fluoroquinolones), Penicillins (NOT effective) 1. **Doxycycline 100 mg BD × 7–14 days** — **FIRST-LINE** for *C. pneumoniae* 2. **Azithromycin 500 mg on day 1, then 250 mg daily × 4 days** — Alternative if doxycycline contraindicated 3. **Fluoroquinolones (moxifloxacin, levofloxacin)** — Effective but reserved for severe disease or intolerance **Clinical Pearl:** Unlike *C. trachomatis*, *C. pneumoniae* responds excellently to macrolides and doxycycline. Fluoroquinolones are effective but not first-line due to cost and resistance concerns. ## Why Other Options Are Wrong ```mermaid flowchart TD A[Persistent cough + fever + interstitial infiltrates]:::outcome --> B{Sputum culture result?}:::decision B -->|Negative on standard media| C[Consider atypical pathogens]:::action C --> D{Serology?}:::decision D -->|C. pneumoniae fourfold rise| E[Atypical pneumonia confirmed]:::outcome E --> F[Doxycycline or macrolide]:::action B -->|Positive| G[Typical bacterial pneumonia]:::outcome G --> H[Beta-lactam ± macrolide]:::action ``` **Fluoroquinolone monotherapy (Option A):** While fluoroquinolones are effective against *C. pneumoniae*, they are NOT first-line. Doxycycline and macrolides are preferred due to lower cost, excellent efficacy, and less resistance. **Tuberculosis (Option C):** TB typically presents with: - Night sweats, weight loss, haemoptysis (not present here) - Upper lobe infiltrates with cavitation (not bilateral interstitial pattern) - Sputum smear positive in 50–80% of pulmonary TB (this patient's sputum culture is negative) - Serological evidence of TB is NOT diagnostic; TB is diagnosed by AFB smear, culture, or GeneXpert MTB/RIF **Viral pneumonia (Option D):** Viral pneumonia is self-limited and does NOT require antibiotics. However, the fourfold rise in *C. pneumoniae* serology makes bacterial atypical pneumonia the diagnosis, not viral infection. ## Additional Diagnostic Pearls **Serology for *C. pneumoniae*:** - **Acute phase:** IgM antibodies appear in first 2–3 weeks - **Convalescent phase:** IgG antibodies peak at 6–8 weeks - **Fourfold rise** in titre between paired sera is diagnostic - Single high titre (≥1:512) is suggestive but not definitive **NAAT (PCR) for *C. pneumoniae*:** More sensitive than serology; can detect organism in respiratory secretions, but not routinely available in all centres. [cite:Harrison 21e Ch 181; Robbins 10e Ch 8; Park 26e Ch 3]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.